Pacira Pharmaceuticals Stock
Price
Target price
€27.00
€27.00
11.570%
2.8
11.570%
€47.53
09.05.24 / Stuttgart Stock Exchange
WKN: A1H68T / Symbol: PCRX / Name: Pacira Pharma / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pacira Pharmaceuticals Stock
A very strong showing by Pacira Pharmaceuticals today, with an increase of €2.80 (11.570%) compared to yesterday's price.
Pacira Pharmaceuticals is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
As a result the target price of 47 € shows a very positive potential of 74.07% compared to the current price of 27.0 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 11.570% | 8.000% | 5.469% | -30.412% | -9.396% | -45.783% | -35.545% |
| Rockwell Medical Inc. | -0.480% | -6.980% | -0.543% | -41.594% | -15.456% | -81.605% | -97.107% |
| Avid Bioservices Inc | -1.900% | 1.307% | 20.155% | -53.030% | 27.049% | -52.160% | 137.839% |
| Gritstone Oncology Inc | -17.770% | -18.396% | -16.952% | -69.813% | -60.845% | -90.515% | - |
Comments
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $40.00 to $38.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Needham & Company LLC from $45.00 to $43.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat